Context Therapeutics: Funding, Investors & Team (Oct 2026)
Context Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for hormone-responsive cancers. The company's flagship product is Apristor (Onapristone XR), a Phase 2 drug being developed for PR+ metastatic breast and ovarian cancers. Additionally, Context is working on CTX-030916, an oral antiprogestin for uterine fibroids and endometriosis, as well as a discovery program targeting Sigma1.
Context Therapeutics has raised $131M across 2 funding rounds on record, the most recent an undisclosed round of $100M announced in May 2024.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Context Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2024.
Context Therapeutics Funding Rounds
Context Therapeutics raised $31.3M in a Post-IPO Equity announced in Dec 2021.
2.4 years later, an undisclosed round of $100M was announced in May 2024.
Context Therapeutics Founders and Leadership Team
Contact details for the Context Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Context Therapeutics Funding Compared to Other Biotechnology Startups
Context Therapeutics' latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Context Therapeutics in Biotechnology and Philadelphia
Companies Similar to Context Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Context Therapeutics Funding FAQs
What does Context Therapeutics do?
Context Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for hormone-responsive cancers. The company's flagship product is Apristor (Onapristone XR), a Phase 2 drug being developed for PR+ metastatic breast and ovarian cancers. Additionally, Context is working on CTX-030916, an oral antiprogestin for uterine fibroids and endometriosis, as well as a discovery program targeting Sigma1.
How much funding has Context Therapeutics raised?
Context Therapeutics has raised $131M across 2 rounds on record. The most recent is an undisclosed round of $100M announced in May 2024.
When did Context Therapeutics last raise funding?
Context Therapeutics' most recent funding round on record is an undisclosed round of $100M, announced in May 2024.
Who founded Context Therapeutics?
FundedIQ lists Martin Lehr (Founder) at Context Therapeutics.
Where is Context Therapeutics headquartered?
Context Therapeutics is based in Philadelphia, Pennsylvania, United States.
How many employees does Context Therapeutics have?
Context Therapeutics is in the 1-10 employee band.
How does Context Therapeutics' funding compare to other Biotechnology startups?
Context Therapeutics' latest round of $100M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Context Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Context Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.